<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71354">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176850</url>
  </required_header>
  <id_info>
    <org_study_id>502.314</org_study_id>
    <nct_id>NCT02176850</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension</brief_title>
  <official_title>Safety, Tolerability and Efficacy of Micardis® (Telmisartan) in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This post-marketing surveillance study was designed to supplement under conditions of normal
      clinical practice the data on the safety, tolerability and efficacy of Micardis® collected
      during the clinical studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <primary_completion_date type="Actual">May 2000</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Indicence of ulcera</measure>
    <time_frame>Up to 6 months after start of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of gastrointestinal (GI) bleedings</measure>
    <time_frame>Up to 6 months after start of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (GI-complaints inclusive)</measure>
    <time_frame>Up to 6 months after start of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in office blood pressure</measure>
    <time_frame>Up to 6 months after start of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 6 months after start of study</time_frame>
    <description>full response: reduction of diastolic blood pressure (DBP) by &gt;= 10 mmHg or final DBP &lt;= 90 mmHg overall response: reduction of DBP by &gt;= 7mmHg or final DBP &lt;= 90 mmHg</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">19870</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Micardis®</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micardis®</intervention_name>
    <arm_group_label>Micardis®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of general practioners, cardiologists and specialist in internal medicine in
        non-hospital practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes with essential hypertension and a minimum age of 18 years

        Exclusion Criteria: (Not applicable)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 7, 2014</lastchanged_date>
  <firstreceived_date>June 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
